The Role of Immunotherapy in Gastrointestinal Cancers: Current Landscape and Future Directions

Julian Medellin^*
*Correspondence: Julian Medellin, Department of Gastroenterology, University of Calgary, Calgary, Canada, Email:

Description

Gastrointestinal cancers pose a significant health burden worldwide. Despite advancements in treatment modalities, the prognosis for many patients remains poor. Immunotherapy has emerged as a promising approach for the treatment of various cancers, including GI cancers. This review provides an overview of the current landscape of immunotherapy in GI cancers, focusing on key agents, mechanisms of action, clinical efficacy, and challenges. Additionally, future directions and potential strategies to enhance the effectiveness of immunotherapy in GI cancers are discussed.

Gastrointestinal cancers, encompassing malignancies of the esophagus, stomach, liver, pancreas, colon, and rectum, are among the leading causes of cancer-related deaths globally [1-3]. Despite advances in early detection and treatment, the prognosis for many GI cancer patients remains poor, necessitating the development of novel therapeutic strategies. Immunotherapy, which harnesses the body's immune system to recognize and eliminate cancer cells, has revolutionized cancer treatment across various malignancies. In recent years, immunotherapy has demonstrated promising results in GI cancers, offering new hope for patients with these challenging diseases.

Checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4 have shown efficacy in GI cancers. Pembrolizumab, nivolumab, and ipilimumab, among others, have gained approval for specific GI cancer subtypes, including advanced hepatocellular carcinoma, gastric/gastroesophageal junction cancer, and colorectal cancer. CAR T-cell therapy, although primarily investigated in hematologic malignancies, is being explored in GI cancers. Preliminary studies have shown potential in targeting antigens such as carcinoembryonic antigen in CRC and glypican-3 in HCC.

Vaccines targeting tumor-associated antigens and oncolytic viruses are being investigated as potential immunotherapeutic strategies in GI cancers, with ongoing clinical trials evaluating their safety and efficacy. The landscape of immunotherapy in gastrointestinal cancers is rapidly evolving, with various approaches showing promise in improving patient outcomes. Checkpoint inhibitors, such as pembrolizumab and nivolumab, have demonstrated efficacy in subsets of GI cancers, including hepatocellular carcinoma, gastric/gastroesophageal junction cancer, and colorectal cancer. These agents work by releasing the brakes on the immune system, allowing it to recognize and attack cancer cells.

CAR T-cell therapy, although more established in hematologic malignancies, is also being explored in GI cancers. Preliminary studies targeting antigens like carcinoembryonic antigen in CRC and glypican-3 in HCC have shown promise, albeit with challenges related to antigen specificity and tumor heterogeneity [4,5]. Additionally, vaccines and oncolytic viruses are being investigated as potential immunotherapeutic strategies in GI cancers. These approaches aim to stimulate an anti-tumor immune response by targeting tumor-associated antigens or directly lysing cancer cells. Despite these advancements, challenges persist, including response heterogeneity, immune-related adverse events, and the development of resistance mechanisms. Combination therapies, biomarker discovery, and personalized approaches are being pursued to overcome these challenges and maximize the benefits of immunotherapy in GI cancers.

Looking ahead, ongoing research efforts are focused on identifying predictive biomarkers, exploring novel immunotherapeutic agents, and developing rational combination strategies to improve outcomes for patients with GI cancers. Immunotherapy has emerged as a promising treatment modality for GI cancers, offering new avenues for improved patient outcomes. Despite significant progress, challenges such as response heterogeneity and resistance need to be addressed. Future research efforts should focus on elucidating biomarkers, exploring combination strategies, and developing personalized approaches to maximize the benefits of immunotherapy in the management of GI cancers.

Acknowledgement

None.

Conflict of Interest

Authors declare no conflict of interest.

References

1. Sousa, Ana Lúcia, Diamantino Sousa, Francisco Velasco and Francisco Açucena, et al. "Rare complication of percutaneous endoscopic gastrostomy: Ostomy metastasis of esophageal carcinoma." World J Gastrointest Oncol 5 (2013): 204.

Google Scholar, Crossref, Indexed at

2. Yeh, Lily, Li‐Hua Lo, Susan Fetzer and Ching‐Huey Chen. "Limited PEG tube use: The experience of long‐term care directions." J Clin Nurs 19 (2010): 2897-2906.

Google Scholar, Crossref, Indexed at

3. Imam, Ashraf, Khalayleh Harbi, Miller Rafael and Khoury Deeb, et al. "Dieulafoy’s lesion related massive Intraoperative gastrointestinal bleeding during single anastomosis gastric bypass necessitating total gastrectomy: A case report." Arch Surg Clin Res 1 (2017): 051-055.

Google Scholar, Crossref, Indexed at

4. Lahner, Edith, Gloria Galli, Gianluca Esposito and Emanuela Pilozzi, et al. "Updated features associated with type 1 gastric carcinoids patients: A single-center study." Scand J Gastroenterol 49 (2014): 1447-1455.

Google Scholar, Indexed at

5. Birda, Chhagan L., Antriksh Kumar and Jayanta Samanta. "Endotherapy for nonvariceal upper gastrointestinal hemorrhage." J Dig Endosc 12 (2021): 078-092.

Google Scholar, Crossref, Indexed at